EN
The first patent for the treatment of nosocomial pneumonia with bacteriophages was issued in Russia. It can save thousands of patients.
The patent was received jointly by the scientists of the RPC "Micromir" and the Federal State Budgetary Scientific Institution "Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology" (FRCC ICMR).
RPC "Micromir"
The invention relates to anesthesiology and critical care, it can be used for the treatment and prevention of recurrence of nosocomial pneumonia in patients in intensive care units.
You are welcome to cite the materials, but be sure to provide an active link to the site. Thank you!
The invention relates to anesthesiology and critical care, it can be used for the treatment and prevention of recurrence of nosocomial pneumonia in patients in intensive care units.
You are welcome to cite the materials, but be sure to provide an active link to the site. Thank you!
Hospital-acquired or nosocomial pneumonia (NP) is one of the most severe infectious complications in intensive care units (ICUs) worldwide, accounting for up to 25% of all infectious complications (1). The incidence of NP ranges from 5 to 20 cases per thousand hospitalizations (2), and mortality from ventilator-associated pneumonia (VAP) alone, a common form of NP, varies from 20 to 50% (3).
Until now, there have been no truly effective methods of treating NP — success largely depended on the speed of diagnosis and the adequacy of antibiotic therapy. Difficulties arise with the latter: in ICUs, patients are exposed to infection with antibiotic-resistant bacteria, including those with a broad spectrum of action. The problem has only worsened over the years, as the WHO lists microbial resistance as one of the 10 threats to global health (4).
Therefore, obtaining the first patent in Russia for the treatment of nosocomial pneumonia using bacteriophages is an important step in ensuring global patient safety. A team of scientists from the RPC "Micromir" and FRCC ICMR formed a complex of bacteriophages active against 14 major NP pathogens, including strains of panresistant bacteria, described the method of their use and confirmed the effectiveness of therapy. It has several significant advantages compared to currently available NP treatments:
Until now, there have been no truly effective methods of treating NP — success largely depended on the speed of diagnosis and the adequacy of antibiotic therapy. Difficulties arise with the latter: in ICUs, patients are exposed to infection with antibiotic-resistant bacteria, including those with a broad spectrum of action. The problem has only worsened over the years, as the WHO lists microbial resistance as one of the 10 threats to global health (4).
Therefore, obtaining the first patent in Russia for the treatment of nosocomial pneumonia using bacteriophages is an important step in ensuring global patient safety. A team of scientists from the RPC "Micromir" and FRCC ICMR formed a complex of bacteriophages active against 14 major NP pathogens, including strains of panresistant bacteria, described the method of their use and confirmed the effectiveness of therapy. It has several significant advantages compared to currently available NP treatments:
- 1Phage therapy allows making treatment targeted — the composition of the complex can be supplemented and adapted to a specific department or institution by selecting the optimal phages to combat the pathogens specific to the ICU.
- 2The method is appropriate for all patients in the same institution. No individual selection of phages is required for each patient, which reduces the duration of treatment and increases its effectiveness.
The principle of therapy is as follows: a ready-made complex containing an adapted composition of bacteriophages is administered to patients by inhalation so that the drug can affect bacterial populations on the mucous membranes of the oropharynx, trachea, larynx, bronchi and alveoli. It also enhances the microbiocenosis of the mucous membranes and the protective properties of the body against viruses, bacteria, protozoa and mycoplasmas.
The positive effect of phage therapy is achieved within 6−24 hours after application, and signs of inflammation reduction are observed already after the first administration of the drug. In patients with inflammatory diseases of the trachea and bronchi, lung function is significantly improved during the use of the complex.
Bacteriophages can be combined with antibiotics, antiseptics (except for Octenisept), hormones, as well as antispasmodics, painkillers and heart medications. The use of the complex is not limited to ICUs, it may help all patients at risk of nosocomial pneumonia. It can be used in oncology, hematology, surgery and other departments.
The positive effect of phage therapy is achieved within 6−24 hours after application, and signs of inflammation reduction are observed already after the first administration of the drug. In patients with inflammatory diseases of the trachea and bronchi, lung function is significantly improved during the use of the complex.
Bacteriophages can be combined with antibiotics, antiseptics (except for Octenisept), hormones, as well as antispasmodics, painkillers and heart medications. The use of the complex is not limited to ICUs, it may help all patients at risk of nosocomial pneumonia. It can be used in oncology, hematology, surgery and other departments.
- Zhang, Y.; Yao, Z.; Zhan, S.; Yang, Z.; Wei, D.; Zhang, J.; Li, J.; Kyaw, M.H. Disease burden of intensive care unit-acquired 528 pneumonia in China: A systematic review and meta-analysis. Int J Infect Dis 2014, 29, 84-90. 529 https://doi.org/10.1016/j.ijid.2014.05.030 530
- Zhu X.; Ge Y.; Wu T.; Zhao K.; Chen Y.; Wu B.; Zhu F.; Zhu B.; Cui L. Co-infection with respiratory pathogens among COVID- 531 2019 cases. Virus Res 2020, 285, 198005. https://doi.org/10.1016/j.virusres.2020.198005 532
- Mirzaei R.; Goodarzi P.; Asadi M.; Soltani A.; Aljanabi H.A.A.; Jeda A.S.; Dashtbin S.; Jalalifar S.; Mohammadzadeh R.; Teimoori 533 A.; Tari K.; Salari M.; Ghiasvand S.; Kazemi S.; Yousefimashouf R.; Keyvani H.; Karampoor S. Bacterial co-infections with SARS- 534 CoV-2. IUBMB Life 2020, 72(10), 2097-2111. https://doi.org/10.1002/iub.2356
Other materials
We write about phage therapy, bacteriophages and their applications, as well as about modern science and Micromir's inner workings.
Any questions?
Contact Us
Phone: +7 (495) 625-32-65
Mail: office@micromir.bio
Mail: office@micromir.bio
© RPC «Micromir»
Veterinary
By using this website, you agree to the use of cookies. We use cookies to provide you with a great experience and to help the website run effectively. More information...
OK